The motivation behind the study stems from a persistent gap in metabolic science. While obesity is projected to affect more than half of the global adult population by 2050, remarkably little is known about the very first events that set the condition in motion in humans. Animal studies have long implicated the intestinal barrier, a single layer of epithelial cells held together by tight junctions that separates the teeming microbial community of the gut lumen from the bloodstream. When this barrier weakens, bacterial components such as lipopolysaccharide, or LPS, can slip into circulation, a phenomenon known as metabolic endotoxemia that has been linked to low-grade inflammation, insulin resistance, and fatty liver disease. But confirming these dynamics in living people has been notoriously difficult, because reliable biomarkers of gut barrier function remain scarce and contested.

To address this, the team designed a gastrointestinal uptake and translocation panel, abbreviated GUT, comprising more than two dozen plasma biomarkers that together capture enterocyte function, mucosal immunity, endotoxin exposure, and epithelial integrity. The twenty participants, all white Danish men with a body mass index around 23, were examined at three time points: before the intervention, immediately after the two-week hypercaloric period, and eight weeks after resuming their habitual lifestyle. The diet consisted of 56 percent carbohydrates, 34 percent fat, and 9 percent protein, delivered as standardized meal boxes emphasizing moderate to high glycemic index foods such as bread, pasta, and polished rice, with fiber intake dropping to an average of just 13 grams per day.

The first striking finding concerned citrulline, a non-protein amino acid synthesized exclusively by enterocytes of the small intestine and widely used as a marker of absorptive capacity. Plasma citrulline rose by approximately 9 percent, from a median of 33.2 to 36.2 micromolar, after the overfeeding period, and returned to baseline eight weeks later. This pattern suggests the intestinal lining responded to the caloric flood by transiently enhancing its absorptive machinery, perhaps through increased villus height or altered permeability, rather than through chronic epithelial expansion. Intriguingly, fasting levels of GLP-2, an intestinotrophic hormone that normally reinforces barrier function and promotes enterocyte proliferation, tended to decline during the intervention, hinting that epithelial renewal may have been temporarily blunted even as absorption ramped up.

The clearest signal of barrier disruption came from zonulin, a physiological modulator of small intestinal permeability that dissociates epithelial tight junctions in response to microbial stimuli. Plasma zonulin roughly doubled after two weeks of overfeeding, a highly significant change that fully reversed at follow-up. Strikingly, zonulin levels correlated strongly with the degree of weight gain: the more a participant’s body mass index, whole body fat, visceral fat mass, and insulin resistance increased, the higher their zonulin climbed. This tight coupling between emerging adiposity and barrier loosening supports a model in which acute overfeeding promotes bacterial encroachment across the gut lining as one of the earliest detectable perturbations, before any overt disease develops.

That encroachment appears to have been met by a targeted mucosal immune response. Anti-LPS immunoglobulin A, the antibody class that patrols mucosal surfaces, increased by about 25 percent during the intervention, while anti-LPS IgG, which reflects systemic antibody exposure, remained unchanged. The researchers interpret this divergence as evidence that bacterial encroachment stayed confined to the mucosal compartment rather than disseminating into the bloodstream. Supporting this, quantitative PCR of bacterial 16S rRNA genes in buffy coat samples from the circulation showed no significant change in bacterial load before and after the diet. Other endotoxemia markers, including LPS-binding protein, CD14, and CD163, also failed to shift consistently, reinforcing the picture of a gut-restricted rather than systemic event.

Yet the liver clearly took notice. Serum amyloid A, an acute-phase protein produced by hepatocytes, surged approximately 2.5-fold within two weeks, accompanied by a more modest but significant rise in high-sensitivity C-reactive protein and a transient increase in interleukin-32, a cytokine previously linked to hepatic steatosis and the severity of metabolic dysfunction-associated steatotic liver disease. These hepatic signals paralleled the liver fat accumulation previously documented in this same cohort. While SAA, hsCRP, and IL-32 largely declined after the recovery period, SAA remained elevated in several individuals, with a median increase of roughly 70 percent from baseline to follow-up, hinting that the hepatic immune system retains a memory of the overfeeding episode.

Perhaps most concerning were the markers that refused to come back down. Intercellular adhesion molecule-1 and vascular cell adhesion molecule-1, which orchestrate leukocyte trafficking across blood vessel walls, and lipocalin-2, a marker of neutrophil activity and intestinal inflammation, either remained elevated or continued rising after participants resumed their normal lives, with VCAM-1 showing a median 35 percent increase at eight-week follow-up. By contrast, a broad panel of classical pro- and anti-inflammatory cytokines, including IL-6, TNF-alpha, and interferon-gamma, showed no consistent changes. The authors caution that part of the sustained adhesion molecule elevation could reflect prior mRNA COVID-19 vaccination, which was widespread in Denmark during the study period, but the overall pattern suggests that brief holiday-style overfeeding may imprint longer-lasting endothelial and neutrophil-associated inflammatory alterations.

The study has limitations worth noting. It included only men, partly because menstrual cycle-related inflammatory fluctuations would confound the endpoints and because women are generally less inclined to voluntarily gain around 5 percent of their body weight. The sample size of twenty and the short follow-up limit the detection of subtler effects, and the lack of intestinal tissue sampling or functional permeability testing means the biomarker story cannot yet be tied directly to structural changes in the gut wall. The prepared meals also followed conventional dietary guidelines rather than emphasizing ultra-processed foods, which previous trials suggest could aggravate metabolic and inflammatory outcomes even further.

Nevertheless, the findings carry an unmistakable message for anyone who views vacation weight gain as harmless. A two-week period of overeating and inactivity, entirely within the range of ordinary real-life behavior, was sufficient to transiently compromise the small intestinal barrier, heighten mucosal immune activation against bacterial products, and ignite a coordinated gut-liver inflammatory response in young, healthy, lean individuals. If such episodes recur year after year, the residual inflammatory signatures observed here could plausibly accumulate, contributing to the immunometabolic remodeling that precedes obesity, type 2 diabetes, and fatty liver disease. The gut, it seems, keeps score far earlier than the bathroom scale does.

Subject of Research: Effects of short-term overfeeding on small intestinal barrier integrity and gut-liver immune activation in healthy men

Article Title: Short term overfeeding disrupts small intestinal barrier integrity and activates hepatic immunity in healthy men

Article References: Nägele, N. S., Suppli, M. P., Gilliam-Vigh, H., Petersen, N., Hartmann, B., Knop, F. K., Lund, A. B., & Jensen, B. A. (2026). Short term overfeeding disrupts small intestinal barrier integrity and activates hepatic immunity in healthy men. iScience, 29(10), Article 117724. https://doi.org/10.1016/j.isci.2026.117724

Image Credits: AI Generated

DOI: 10.1016/j.isci.2026.117724

Keywords: overfeeding, intestinal barrier, zonulin, metabolic endotoxemia, gut-liver axis, serum amyloid A, anti-LPS IgA, citrulline, insulin resistance, obesity, inflammation, iScience

The new study, published in the Springer journal Veterinary Oncology, evaluated two candidate blood biomarkers across an unusually broad spectrum of equine tumors. Serum thymidine kinase 1, or TK1, is an enzyme central to DNA synthesis that becomes upregulated in rapidly dividing cancer cells and leaks into the circulation, where its activity can be measured. It has already attracted attention in human oncology and in canine medicine, particularly for hematopoietic cancers. Serum amyloid A, or SAA, is the major acute-phase protein of the horse, produced by the liver in response to inflammatory cytokines and widely used in equine practice to monitor infection and inflammation, yet it had never been systematically assessed as a tumor marker. The researchers, led by Lucia Unger of the Swiss Institute of Equine Medicine in Bern together with colleagues at the Swedish University of Agricultural Sciences, set out to determine whether either molecule could reliably distinguish tumor-bearing equids from healthy and sick but cancer-free animals.

The team drew on the tumor biobank of the Institut Suisse de Médecine Equine, assembling serum samples from 91 equids with histologically or clinically confirmed cancers and 149 control horses. The tumor cohort spanned eight groups: 14 cases of lymphoma, 8 of (adeno)carcinoma, 4 of hemangiosarcoma, 8 of other solid internal tumors, 11 of ovarian granulosa cell tumor, 14 of sarcoid, 17 of squamous cell carcinoma and 15 of melanoma. Crucially, the control group was split into 42 healthy horses and 107 horses suffering from non-neoplastic diseases, a design choice that directly tested whether the biomarkers rise because of cancer itself or merely because of general illness and inflammation. All 240 samples were analyzed for TK1 activity using a radiochemical assay with tritium-labeled thymidine as the natural substrate, while SAA concentrations were measured by enzyme-linked immunosorbent assay in a subset of 112 samples.

The technical details of the TK1 assay matter, because the field has been burned before. A commercially available chemiluminescence immunoassay that uses the synthetic substrate azidothymidine instead of thymidine has previously failed to diagnose equine lymphoma reliably, an outcome now explained by the finding that equine TK1 reacts with azidothymidine at only about 55 percent of the rate measured with the natural substrate. The tritium-labeled thymidine approach avoids this pitfall. In the new work, tumor samples were run in triplicate across two independent assay runs, producing six measurements per sample, and the investigators applied rigorous statistical testing, including Mann-Whitney U comparisons with Bonferroni correction for multiple comparisons and effect size calculations to quantify the magnitude of differences between groups.

The headline result was striking. Serum TK1 activity was significantly elevated in equids with lymphoma, other solid internal tumors, sarcoid, squamous cell carcinoma and melanoma compared with both healthy controls and controls with non-neoplastic comorbidities, with effect sizes ranging from moderate to large. In contrast, horses with (adeno)carcinoma, hemangiosarcoma or ovarian granulosa cell tumor generally did not show significant elevations, with the exception of hemangiosarcoma cases, which had modestly higher TK1 than the diseased control group. Receiver operating characteristic analysis reinforced the pattern: the area under the curve, a standard measure of diagnostic accuracy, was rated excellent for lymphoma, hemangiosarcoma, other solid internal tumors, sarcoid, squamous cell carcinoma and melanoma, with values between 0.90 and 0.98 in comparisons against both control groups, and good for ovarian granulosa cell tumor at around 0.75. Only carcinoma fell into the poor-to-fair range and did not reach statistical significance, indicating that TK1 is not currently a reliable marker for this heterogeneous group.

To translate laboratory statistics into clinical meaning, the researchers calculated post-test probabilities for the three tumor types with known prevalence in comparable equine populations: lymphoma at 0.002 to 0.5 percent, sarcoid at 19 percent, and melanoma at 40 to 80 percent in grey horses. For lymphoma, where the disease is extremely rare, a positive TK1 result only modestly increased the probability of cancer and a negative result barely lowered it, meaning the test cannot serve as a population-wide screening tool. For sarcoid and melanoma, however, where pre-test probability is moderate to high, a positive result substantially increased the likelihood of disease and a negative result reduced it essentially to zero, regardless of whether controls had other illnesses. In practical terms, for a grey horse with a suspicious lump or a horse whose biopsy is impractical, a TK1 measurement could meaningfully sharpen the diagnostic picture.

SAA told a very different story. Despite its central role as the horse’s principal acute-phase protein, SAA concentrations did not differ significantly between any of the eight tumor groups and the diseased control horses. The finding underscores a fundamental limitation of inflammation-based markers: tumors do not always provoke the systemic inflammatory response that drives hepatic acute-phase protein production, and when inflammation is present, non-neoplastic conditions produce it just as vigorously. The result parallels mixed evidence from other species, where C-reactive protein shows promise in canine cancer but SAA has not been validated as a relapse marker in dogs with multicentric lymphoma, even though cats with lymphoma do show elevated SAA that declines with successful treatment. For equine practitioners, the message is that SAA remains an excellent inflammation marker but has no place as a cancer diagnostic.

The study also surfaced intriguing biological nuances. TK1 activity correlated weakly but significantly and negatively with age among control horses, with younger animals showing higher levels, possibly reflecting greater cellular turnover in growing tissue. Because horses affected by sarcoids were younger than the healthy control group, the authors examined whether age could explain their elevated TK1, but the effect persisted when sarcoid cases were compared with the more age-matched diseased control group, supporting a genuine association with the tumor. One horse with multicentric lymphoma and extensive metastases displayed exceptionally high TK1 activity of 17.72 pmol/min/mL, echoing human data in which serum TK1 rises with metastatic burden in melanoma, lung, gastric and colorectal cancers. In dogs with lymphoma, serial TK1 monitoring tracks disease progression and treatment response, raising the prospect that repeated measurement could one day serve a similar prognostic role in horses. Meanwhile, the three highest values among diseased controls came from horses with severe inflammatory conditions, including extensive necrotic lipoma, cellulitis and endotoxemia with laminitis, a cautionary observation that inflammation may occasionally confound the test.

The authors are careful about the limits of their work. Several tumor groups, particularly carcinoma, hemangiosarcoma and other solid internal tumors, were small and heterogeneous, making those results exploratory, and no power calculation was possible for SAA. Yet for lymphoma the minimal required sample size was met, and the findings for sarcoid, squamous cell carcinoma and melanoma rest on the largest cohorts. The bigger obstacle is practical: the tritium-labeled thymidine assay requires radiochemical laboratory infrastructure that few veterinary diagnostic services possess, while the commercial chemiluminescence alternative is unreliable in horses. The researchers call for the development of a horse-specific TK1 ELISA or point-of-care test that could bring the assay into routine practice, and for multicenter studies to validate the cut-offs in larger, prospectively recruited cohorts.

If those steps succeed, the implications for animal welfare are considerable. A validated blood test would spare horses invasive biopsies and exploratory surgeries, help clinicians decide when treatment is justified, and potentially enable monitoring of recurrence in tumors like sarcoids, which recur unpredictably after treatment. The study also clarifies that TK1 is not a lymphoma-specific marker but a broad proliferation signal shared across equine neoplasia, mirroring its behavior in human oncology where it performs best in combination with other tests rather than alone. For a field that has long lagged behind small-animal and human cancer diagnostics, this work marks a credible first step toward non-invasive, blood-based tumor detection in horses, built on a decade of careful enzyme biochemistry and one of the largest equine tumor serum collections ever assembled.

Subject of Research: Evaluation of serum thymidine kinase 1 and serum amyloid A as blood-based tumor biomarkers in equids

Article Title: Evaluation of serum thymidine kinase 1 and serum amyloid A as tumor biomarkers in equids: a comparative cross-sectional study

Article References: Unger, L., Rayhan, A. B. H., Sharif, H., Gerber, V., Rönnberg, H., Eriksson, S., & Wang, L. (2026). Evaluation of serum thymidine kinase 1 and serum amyloid A as tumor biomarkers in equids: a comparative cross-sectional study. Veterinary Oncology, 3(1), Article 6. https://doi.org/10.1186/s44356-026-00057-4

Image Credits: AI Generated

DOI: 10.1186/s44356-026-00057-4

Keywords: thymidine kinase 1, serum amyloid A, equine cancer, biomarkers, lymphoma, sarcoid, melanoma, squamous cell carcinoma, veterinary oncology, liquid biopsy, diagnostics, horses